Integrated one-stop solution for mRNA CMC

Speaker: Dr. Xiao Pan, Director of Platform R&D Dept., ProBio
Date: Mar. 28^th, 2023
Time: 13:00-14:00 (GMT+8:00)

Biography

Dr. Pan Xiao, Director of Platform R&D Department, manages the platform R&D department to develop antibody, protein, and gene cell therapy related process platforms. Dr. Xiao Pan received his Ph.D. from the Department of Bioengineering, Wageningen University, the Netherlands. Prior to joining ProBio, he worked at FujiFilm Diosynth Biotechnologies UK as principal scientist.

Dr. Pan joined ProBio in 2018, responsible for process development, including process design, development, scale-up and characterization. He led the CMC work of more than 20 IND projects. Since 2020, Dr. Pan is in charge of Platform R&D developed intensified antibody process platform, AAV suspension process platform, and mRNA process platform.

Background

The production of mRNA therapeutics and vaccines is a complex process that begins with pDNA manufacturing and ends with fill and finish by using different delivery technologies. Currently, there are some mRNA candidates in late-stage trials or commercial stage. The CDMOs that involved those drug development cycles usually support one aspect of the process, such as pDNA production, mRNA production or LNP formulation, etc. With strong plasmid process development, manufacturing capabilities and global project experience, ProBio establishes the high-quality services in the field of mRNA, providing customers with one-stop solutions from plasmids to mRNA, including plasmids and linearized DNA manufacturing, in vitro transcription of mRNA (IVT-mRNA), lipid nanoparticle (LNP) formulation and sterile filling.